Efficacy of first line CDK4/6 inhibitors in HER2-low vs HER2-zero, hormone receptor positive, HER2 negative metastatic breast cancer

被引：4
|
作者：
Sanchez-Bayona, Rodrigo
Teran, Santiago
De Torre, Ana Sanchez
Alva, Manuel
Lema, Laura
Manso, Luis
Toledo, Estefania
Roncero, Ana Maria
Merino, Cristina
Martinez, Mario
Parrilla, Lucia
Ciruelos, Eva
Tolosa, Pablo
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-P5-13-24
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-13-24
引用
收藏
页数：3
相关论文
共 50 条
  • [1] The association of HER2 low expression with the efficacy of CDK4/6 inhibitor in hormone receptor positive HER2 negative metastatic breast cancer.
    Bao, Kelvin K. H.
    Sutanto, Leone
    Tse, Shirley S. W.
    Cheung, Ka Man
    Chan, Jeffrey C. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Hormone receptor-positive HER2-low metastatic breast cancer (mBC): evolution of HER2 status after CDK4/6 inhibitor treatment
    de Nonneville, Alexandre
    Finetti, Pascal
    Boudin, Laurys
    Usclade, Lucas
    Mescam, Lenaig
    Durieux, Emeline
    Boucraut, Agathe
    Viret, Frederic
    Mamessier, Emilie
    Goncalves, Anthony
    Bertucci, Francois
    CANCER RESEARCH, 2024, 84 (09)
  • [3] Impact of HER2-low and HER2-zero status on metastatic hormonal receptor-positive breast cancer patients treated with first-line aromatase inhibitors, with or without CDK4/6 inhibitors: A multicenter retrospective analysis
    Susiriwatananont, T.
    Wongkraisri, C.
    Dajsakdipon, T.
    Supavavej, A.
    Dechaphunkul, A.
    Sunpaweravong, P.
    Neesanun, S.
    Ithimakin, S.
    Dejthevaporn, T.
    Parinyanitikul, N.
    ANNALS OF ONCOLOGY, 2024, 35 : S1420 - S1420
  • [4] Differences in Treatment Outcomes Between Patients with HER2-Low versus HER2-Zero, Hormone Receptor-Positive Advanced-Stage Breast Cancer Treated with CDK4/6 Inhibitors
    Sharaf, Baha'
    Abu-Fares, Hala
    Tamimi, Faris
    Al-Sawajneh, Suhaib
    Salama, Osama
    Daoud, Rand
    Alhajahjeh, Abdulrahman A.
    Al-Lababidi, Sawsan
    Abdel-Razeq, Hikmat
    CANCER RESEARCH, 2023, 83 (05)
  • [5] Clinical effectiveness of CDK4/6 inhibitors in HER2-low metastatic breast cancer
    Zhang, Frank
    Mesias, Jesus Anampa
    CANCER RESEARCH, 2024, 84 (09)
  • [6] Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer
    Migliaccio, Ilenia
    Leo, Angela
    Galardi, Francesca
    Guarducci, Cristina
    Fusco, Giulio Maria
    Benelli, Matteo
    Di Leo, Angelo
    Biganzoli, Laura
    Malorni, Luca
    CANCERS, 2021, 13 (11)
  • [7] Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm
    Boyle, Frances
    Beith, Jane
    Burslem, Katie
    de Boer, Richard
    Hui, Rina
    Lim, Elgene
    McCarthy, Nicole
    Redfern, Andrew
    Woodward, Natasha
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 3 - 11
  • [8] HER2-LOW POSITIVE AND HER2-ZERO BREAST CANCERS ARE CLINICALLY DISTINCT
    不详
    CANCER DISCOVERY, 2021, 11 (09) : 2124 - 2124
  • [9] HER2-low vs HER2-zero metastatic breast carcinoma: A clinical and genomic descriptive analysis
    Sanchez Bayona, R.
    Luna, A. M.
    Tolosa, P.
    Sanchez De Torre, A.
    Castelo, A.
    Marin, M.
    Garcia, C.
    Boni, V.
    Bernal Hertfelder, E.
    Vega, E.
    Rojas, B.
    Bratos, R.
    Martinez, M.
    Diaz Bermejo, A. J.
    Lema, L.
    Manso, L.
    Ciruelos, E. M.
    ANNALS OF ONCOLOGY, 2021, 32 : S29 - S30
  • [10] Prognosis in HR-positive metastatic breast cancer with HER2-low versus HER2-zero treated with CDK4/6 inhibitor and endocrine therapy: a meta-analysis
    Xia, Lin-Yu
    Cao, Xu-Chen
    Hu, Qing-Lin
    Xu, Wei-Yun
    FRONTIERS IN ONCOLOGY, 2024, 14
12345